Relieving the Weight: Fenfluramine’s Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome
As seen through the results of multiple clinical trials, fenfluramine can provide significant seizure reduction for Lennox-Gastaut and Dravet patients with treatment-resistant seizures. Risks can be mitigated through adherence to proper programs and schedules, and can provide enough benefits to outweigh risks in patients with particularly resistant epilepsies.
Authors
- Harn Shiue (ORCID: https://orcid.org/0000-0002-0024-2646)
- Matthew T. Hoerth
- Simone A. McCay (ORCID: https://orcid.org/0009-0009-8641-5568)
Institutions
- Mayo Clinic Hospital (US)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/10600280251396957
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47